Navigation Links
Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
Date:4/17/2008

PALO ALTO, Calif., April 17 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK), a biopharmaceutical company focused on discovering and developing drugs to treat serious diseases, today announced that it made four preclinical data presentations at the 99th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, Calif. The abstracts highlighted results from Telik's Research and Development programs.

Identification and Characterization of Novel Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor 2 [Abstract # 1439]

Inhibition of the vascular endothelial growth factor receptor signaling

pathway with antibodies or small molecules has been proven effective as an

anti-cancer therapy. Through the use of Telik's Target-Related Affinity

Profiling (TRAP(R)) screening technology, novel inhibitors of VEGFR2

kinase were discovered. The inhibitors belong to nine structural classes,

among which E2B8 and EAAF are sub-micromolar inhibitors of the kinase.

Mechanism of Induction of Apoptosis by TLK199 (TELINTRA(R)) in Human Leukemia Cell Lines [Abstract # 2270]

Telik researchers conducted studies with data highlighting TLK199, a novel

glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1,

which induces apoptosis, or programmed cell death, in human HL60

promyelocytic cells and TF-1 erythroleukemic cells. Treatment of the

leukemia cells with TLK199 also resulted in an increase of the

phosphorylation of eIF2alpha, a key signaling event in the integrated

stress response (ISR), and in induction of multiple genes implicated in

ISR. Telik currently has ongoing studies of TLK199 in clinical

development for the treatment of myelodysplastic syndrome (MDS).

Identification of a Novel Class of Nonpeptidyl Small-Molecule Inhibitors of the Human Proteasome [Abstract # 3271]

The ubiquitin-proteasome system (UPS) mediated protein turnover underlies

many signaling pathways that are fundamental to cell proliferation,

survival and death. Many important cellular proteins that are

dysregulated in cancer are proteasome substrates. Telik researchers have

identified multiple nonpeptidyl small-molecule hits that inhibited human

proteasome activity both biochemically and in cells. The best series

exhibited many desirable features including excellent cellular specificity,

equal activity against all three proteolytic sites of the proteasome, and

potent and broad anti-tumor activity in vitro.

Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer Drug Discovery at Telik [Abstract # 4754]

Compounds for these preclinical studies came through the use of Telik's

TRAP technology, which provides an alternative screening method that is

based on a unique molecular descriptor called an affinity fingerprint. An

affinity fingerprint is based on the binding energy of small molecules to

proteins. Advanced computational methods are used to determine affinity

fingerprints, and to select compounds for screening. Advantages to using

TRAP include: a "low throughput" approach using complex, physiologically

relevant assays; identification of small molecule drug leads after testing

as few as 200 compounds; high level of success against a wide range of

cancer targets; enables scaffold hopping; and can speed the optimization

of small molecule drugs.

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
2. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
3. Telik Announces Year-End Financial Release, Conference Call and Webcast
4. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
5. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
6. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
7. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
8. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
9. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
10. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
11. SGX Presents Preclinical MET Data at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... investments in recruiting top industry experts, and expanding its LATAM network and logistics ... tools for clients to manage their clinical trial projects. , The expansion will ...
(Date:4/27/2016)... ... ... Cambridge Semantics, the leading provider of Smart Data analytic and data ... to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” , ... of end users facing some of the most complex data challenges in the industry,” ...
(Date:4/27/2016)... ... , ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” ... of Committee since 1987. Since then, he has served in a number of key ... for both the program and exposition committees. In his professional career, Dr. Gardner is ...
(Date:4/27/2016)... Columbia , April 27, 2016 ... "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... Anschluss an ihre Pressemitteilung vom 13. August 2015 ... hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten auf ... Kanadische Dollar zu bringen. Davon wurden 157.900.000 Einheiten ...
Breaking Biology Technology:
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/14/2016)... Florida , March 14, 2016 ... the growing mobile commerce market, announces the airing of a ... channels starting the week of March 21 st .  The ... CNBC, including its popular Squawk on the Street show. ... focused on the growing mobile commerce market, announces the airing ...
Breaking Biology News(10 mins):